Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RNAI stocks are going to be the biggest driver in biotech in the through 2030 WAVE and PRQR These could be the next ALNY 450 drugs in the pipeline worldwide for RNAI drugs. $WVE
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Dystrophin results from a pre-specified analysis of ambulatory boys showed: Mean absolute muscle content-adjusted dystrophin expression was 9.0% (range: 4.6-13.9%) and mean absolute unadjusted dystrophin expression was 5.5% of normal (range: 3.3-8.3%), as measured by Western Blot. [...] 89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%.